2 Warren Buffett Stocks to Buy and Hold Forever

Motley Fool2022-02-17

Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

422

Report

Comment（123）

koolgal
·2022-02-18
Apple and AbbVie - 2 great stocks to buy and hold forever! 🚀🚀🚀🌙🌙🌙💰💰💰
Reply
1
Report
6af1eba7
·2022-02-17
Nice
Reply
Like
Report
KCLEE123
·2022-02-17
Good recommendations
Reply
1
Report
Johnlimwt
·2022-02-17
Buy
Reply
1
Report
TeslaLegend
·2022-02-17
Nice
Reply
1
Report
WDnemo
·2022-02-17
Apple is good but left the ship and it's now quite high to get back onboard
Reply
2
Report
Sunris3
·2022-02-17
Ok
Reply
3
Report
AmitS
·2022-02-17
Cool
Reply
3
Report
ac1887
·2022-02-17
Good
Reply
4
Report
SallyNeo
·2022-02-17
Ok
Reply
3
Report
thecham
·2022-02-17
Ok
Reply
3
Report
neosg
·2022-02-17
Like please
Reply
2
Report
pb328
·2022-02-17
Nice
Reply
4
Report
amazinggrace
·2022-02-17
Please like too thanks
Reply
2
Report
Huntsilencer
·2022-02-17
Up
Reply
4
Report
jwee
·2022-02-17
Oooo
Reply
5
Report
Gibbie
·2022-02-17
Yes
Reply
5
Report
AE2
·2022-02-17
Always good to have Apple shares, will consider ABBV too! However, ABBV is at its 52 week high now
Reply
5
Report
JayWin
·2022-02-17
Please reply and like, thanks
Reply
5
Report
Fold Replies
- TTH4Legs:
  .
  2022-02-17
  Reply
  Report
- amazinggrace:
  Ok done!
  2022-02-17
  Reply
  Report
WILLIS
·2022-02-17
Nice 👍
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2211661523?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-17 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2211661523","market":"us","top_or_hot":-1,"title":"2 Warren Buffett Stocks to Buy and Hold Forever","media":"Motley Fool","content":"<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRK.B","symbol_name":"伯克希尔B","start_time":0,"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","article_id":"2211661523","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","pubTimestamp":1645057250,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BRK.B":"伯克希尔B","BK4170":"电脑硬件、储存设备及电脑周边","BK4176":"多领域控股","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","AAPL":"苹果","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BK4527":"明星科技股","BK4501":"段永平概念","BK4559":"巴菲特持仓","ABBV":"艾伯维公司","BK4550":"红杉资本持仓","BRK.A":"伯克希尔","BK4505":"高瓴资本持仓"},"translate_title":"2股沃伦·巴菲特的股票要买并永远持有","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"AAPL":1,"BRK.B":0.71,"BRK.A":0.71},"content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9094252862,"gmtCreate":1645158248249,"gmtModify":1676534004645,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":6,"crmLevelSwitch":1,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"htmlText":"Apple and AbbVie - 2 great stocks to buy and hold forever! 🚀🚀🚀🌙🌙🌙💰💰💰","listText":"Apple and AbbVie - 2 great stocks to buy and hold forever! 🚀🚀🚀🌙🌙🌙💰💰💰","text":"Apple and AbbVie - 2 great stocks to buy and hold forever! 🚀🚀🚀🌙🌙🌙💰💰💰","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094252862","repostId":2211661523,"repostType":2,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094891471,"gmtCreate":1645104446998,"gmtModify":1676533997271,"author":{"id":"4107399600934100","authorId":"4107399600934100","name":"6af1eba7","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4107399600934100","authorIdStr":"4107399600934100"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094891471","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094168743,"gmtCreate":1645086405735,"gmtModify":1676533995632,"author":{"id":"3573996683897806","authorId":"3573996683897806","name":"KCLEE123","avatar":"https://community-static.tradeup.com/news/efadbd613eadf4feafab52913d9301b4","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":3,"crmLevelSwitch":0,"idStr":"3573996683897806","authorIdStr":"3573996683897806"},"htmlText":"Good recommendations&nbsp;","listText":"Good recommendations&nbsp;","text":"Good recommendations","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094168743","repostId":2211661523,"repostType":2,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094181530,"gmtCreate":1645081381602,"gmtModify":1676533995404,"author":{"id":"3578545886341911","authorId":"3578545886341911","name":"Johnlimwt","avatar":"https://static.tigerbbs.com/a1adeee2347b67dfd778339494a5fd26","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578545886341911","authorIdStr":"3578545886341911"},"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094181530","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094181679,"gmtCreate":1645081380750,"gmtModify":1676533995396,"author":{"id":"3572489627147183","authorId":"3572489627147183","name":"TeslaLegend","avatar":"https://static.tigerbbs.com/180ad6f06095bcbf2b6594d26c494752","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":4,"crmLevelSwitch":1,"idStr":"3572489627147183","authorIdStr":"3572489627147183"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094181679","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094181339,"gmtCreate":1645081344456,"gmtModify":1676533995388,"author":{"id":"3575333960287526","authorId":"3575333960287526","name":"WDnemo","avatar":"https://static.tigerbbs.com/2241a941fc1eb6cca28c7a714cba1571","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3575333960287526","authorIdStr":"3575333960287526"},"htmlText":"Apple is good but left the ship and it's now quite high to get back onboard","listText":"Apple is good but left the ship and it's now quite high to get back onboard","text":"Apple is good but left the ship and it's now quite high to get back onboard","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094181339","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094181068,"gmtCreate":1645081321578,"gmtModify":1676533995380,"author":{"id":"3581632171272762","authorId":"3581632171272762","name":"Sunris3","avatar":"https://static.tigerbbs.com/b069abdd5543b78374d0994f89a22816","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581632171272762","authorIdStr":"3581632171272762"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094181068","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094183264,"gmtCreate":1645081213779,"gmtModify":1676533995365,"author":{"id":"3576139359058481","authorId":"3576139359058481","name":"AmitS","avatar":"https://static.tigerbbs.com/30b36e4e0298251a0c7c51af5f6291d0","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3576139359058481","authorIdStr":"3576139359058481"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094183264","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094183685,"gmtCreate":1645081151077,"gmtModify":1676533995372,"author":{"id":"3585352116267703","authorId":"3585352116267703","name":"ac1887","avatar":"https://static.tigerbbs.com/a4f5865f79452e7da123e88ff35959e5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585352116267703","authorIdStr":"3585352116267703"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094183685","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094189702,"gmtCreate":1645080813665,"gmtModify":1676533995348,"author":{"id":"3569657483407888","authorId":"3569657483407888","name":"SallyNeo","avatar":"https://static.tigerbbs.com/36144116caeba1af1d2ccbebeffac342","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569657483407888","authorIdStr":"3569657483407888"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094189702","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094189418,"gmtCreate":1645080811337,"gmtModify":1676533995348,"author":{"id":"3561295030711071","authorId":"3561295030711071","name":"thecham","avatar":"https://static.tigerbbs.com/5930d84090e4f5182904005dab162bd6","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":1,"idStr":"3561295030711071","authorIdStr":"3561295030711071"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094189418","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094189596,"gmtCreate":1645080797619,"gmtModify":1676533995340,"author":{"id":"3571113797749536","authorId":"3571113797749536","name":"neosg","avatar":"https://static.tigerbbs.com/fc9ad7a3430e4784449db6c7be4fa003","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":2,"crmLevelSwitch":1,"idStr":"3571113797749536","authorIdStr":"3571113797749536"},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094189596","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094180204,"gmtCreate":1645080292659,"gmtModify":1676533995324,"author":{"id":"3581984599043002","authorId":"3581984599043002","name":"pb328","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581984599043002","authorIdStr":"3581984599043002"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094180204","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":638317969,"gmtCreate":1645080034887,"gmtModify":1676532731836,"author":{"id":"3581927793488898","authorId":"3581927793488898","name":"amazinggrace","avatar":"https://static.tigerbbs.com/101230c6fb2ec15140a58f9488ad7396","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3581927793488898","authorIdStr":"3581927793488898"},"htmlText":"Please like too thanks","listText":"Please like too thanks","text":"Please like too thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/638317969","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9094117635,"gmtCreate":1645079774225,"gmtModify":1676533995317,"author":{"id":"3583029437333652","authorId":"3583029437333652","name":"Huntsilencer","avatar":"https://static.tigerbbs.com/9b69d6b5db7ba7ec92be9ac8c5c5705c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3583029437333652","authorIdStr":"3583029437333652"},"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094117635","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094117801,"gmtCreate":1645079771595,"gmtModify":1676533995316,"author":{"id":"3570833313854293","authorId":"3570833313854293","name":"jwee","avatar":"https://static.tigerbbs.com/a28abfe41bb5b560d49fb6f273c7de99","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570833313854293","authorIdStr":"3570833313854293"},"htmlText":"Oooo","listText":"Oooo","text":"Oooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094117801","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094114004,"gmtCreate":1645079227737,"gmtModify":1676533995268,"author":{"id":"3564398446314499","authorId":"3564398446314499","name":"Gibbie","avatar":"https://static.tigerbbs.com/ac29ad2a0a11289a908ae00b770dc0c5","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3564398446314499","authorIdStr":"3564398446314499"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094114004","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094112478,"gmtCreate":1645078952516,"gmtModify":1676533995180,"author":{"id":"4104406149093920","authorId":"4104406149093920","name":"AE2","avatar":"https://community-static.tradeup.com/news/936b603ad820012fc76e5eb573cd7224","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4104406149093920","authorIdStr":"4104406149093920"},"htmlText":"Always good to have Apple shares, will consider ABBV too! However, ABBV is at its 52 week high now","listText":"Always good to have Apple shares, will consider ABBV too! However, ABBV is at its 52 week high now","text":"Always good to have Apple shares, will consider ABBV too! However, ABBV is at its 52 week high now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094112478","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":638312376,"gmtCreate":1645078874635,"gmtModify":1676532731763,"author":{"id":"3581832598723204","authorId":"3581832598723204","name":"JayWin","avatar":"https://static.tigerbbs.com/e7fe632cbb77a4bc57ba97f59aeb8162","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581832598723204","authorIdStr":"3581832598723204"},"htmlText":"Please reply and like, thanks&nbsp;","listText":"Please reply and like, thanks&nbsp;","text":"Please reply and like, thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/638312376","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100568073,"gmtCreate":1645079735534,"gmtModify":1663243938555,"authorId":3576220386239608,"author":{"id":3576220386239608,"idStr":"3576220386239608","authorId":3576220386239608,"name":"TTH4Legs","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.06","exceedPercentage":"60.42%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":638312376,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":7250133,"gmtCreate":1645080043083,"gmtModify":1663239827732,"authorId":3581927793488898,"author":{"id":3581927793488898,"idStr":"3581927793488898","authorId":3581927793488898,"name":"amazinggrace","avatar":"https://static.tigerbbs.com/101230c6fb2ec15140a58f9488ad7396","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.15","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":638312376,"type":1,"supId":0,"prevId":0,"content":"Ok done!","text":"Ok done!","html":"Ok done!"}],"langContent":"CN"},{"id":9094116797,"gmtCreate":1645078703232,"gmtModify":1676533995164,"author":{"id":"3586769796613127","authorId":"3586769796613127","name":"WILLIS","avatar":"https://static.tigerbbs.com/e1222dd0edb3b89cfb982d29ac29fc52","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3586769796613127","authorIdStr":"3586769796613127"},"htmlText":"Nice 👍","listText":"Nice 👍","text":"Nice 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094116797","repostId":2211661523,"repostType":4,"repost":{"id":"2211661523","pubTimestamp":1645057250,"share":"https://ttm.financial/m/news/2211661523?lang=&edition=fundamental","pubTime":"2022-02-17 08:20","market":"us","language":"en","title":"2 Warren Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2211661523","media":"Motley Fool","summary":"The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.","content":"<html><head></head><body><p>Warren Buffett, CEO of multinational conglomerate <b>Berkshire Hathaway</b>, is widely regarded as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.</p><p>Buffett oversees his company&#39;s investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker <b>AbbVie</b> (NYSE:ABBV) and tech giant <b>Apple</b> (NASDAQ:AAPL). Here&#39;s why.</p><p><img src=\"https://static.tigerbbs.com/cbce34f9cdc257bf6d296c2baea0e809\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>ABBV Total Return Level data by YCharts</p><h2>1. AbbVie</h2><p>Pharmaceutical companies have the advantage of offering products that are always in demand. AbbVie&#39;s portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.</p><p>In 2021, AbbVie&#39;s net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That&#39;s a solid top-line performance for a pharma giant. The drugmaker&#39;s adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie&#39;s Humira made up almost 37% of the company&#39;s total revenue last year.</p><p>That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira&#39;s loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.</p><p>Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira&#39;s indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.</p><p>Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company&#39;s products boast patents that won&#39;t expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company&#39;s revenue base routinely.</p><p>AbbVie&#39;s solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.</p><p>That&#39;s just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.</p><h2>2. Apple</h2><p>Apple&#39;s iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.</p><p>Could Apple lose its dominance in the smartphone market? It wouldn&#39;t be the first time something like that happens. Apple itself played an instrumental role in the decline of <b>BlackBerry</b>&#39;s once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?</p><p>Given how popular and powerful the company&#39;s brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.</p><p>The company&#39;s services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple&#39;s services revenue grows -- and as it captures a larger share of the company&#39;s total revenue -- that will work wonders for the company&#39;s bottom line.</p><p>iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company&#39;s future is increasingly tied to its services segment, and that&#39;s something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett&#39;s portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边","AAPL":"苹果","BK4176":"多领域控股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BRK.A":"伯克希尔","BK4507":"流媒体概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BRK.B":"伯克希尔B","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4550":"红杉资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211661523","content_text":"Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE:ABBV) and tech giant Apple (NASDAQ:AAPL). Here's why.ABBV Total Return Level data by YCharts1. AbbViePharmaceutical companies have the advantage of offering products that are always in demand. AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Venclexta; and schizophrenia treatment Vraylar.In 2021, AbbVie's net revenue came in at $56.1 billion, 10.5% higher than the year-ago period. That's a solid top-line performance for a pharma giant. The drugmaker's adjusted earnings per share for the year increased 20.3% to $12.70. Note that AbbVie's Humira made up almost 37% of the company's total revenue last year.That is a problem since the healthcare company will lose patent exclusivity for this medicine in the U.S. next year. Humira's loss of patent exclusivity in Europe back in 2018 significantly harmed its international revenue.Still, the company is prepared to deal with the inevitable revenue losses Humira will experience in the U.S. in the coming years. Skyrizi and Rinvoq are well on their way to earning approvals across most of Humira's indications, and they already have significant wins under their belt. In 2021, Sales of Rinvoq more than doubled to $1.7 billion while revenue from Skyrizi increased by 85% to $2.9 billion.Skyrizi and Rinvoq seem well-equipped to fill the gaping hole that Humira will leave, but the company can count on its other products as well, including its Botox franchise. Many of the company's products boast patents that won't expire anytime soon. Plus, AbbVie has a pipeline with dozens of ongoing programs. Expect new approvals and label expansions to add to the company's revenue base routinely.AbbVie's solid business helps support its excellent dividend track record. The company is part of the exclusive club of Dividend Kings, or companies that have raised their payouts for at least 50 consecutive years. And with an above-average yield of 3.74% and a conservative payout ratio of 42%, AbbVie looks more than able to sustain further dividend increases ahead.That's just one more reason to purchase shares of this pharma giant. Overall, AbbVie looks like a solid company to hold on to through thick and thin.2. AppleApple's iPhone has been immensely successful since it was introduced in 2007. The company remains a leader in this industry with a 22% share of the smartphone market in the fourth quarter of 2021. During its fiscal year 2021 (ended Sept. 25), Apple generated $192 billion in sales from its iPhone segment, 39.3% higher than the previous fiscal year.Could Apple lose its dominance in the smartphone market? It wouldn't be the first time something like that happens. Apple itself played an instrumental role in the decline of BlackBerry's once-booming smartphone business starting in the late 2000s. Could other companies permanently dethrone Apple?Given how popular and powerful the company's brand has become, it is hard to imagine Apple no longer being one of the most prominent players in this field, at least for the foreseeable future. More importantly, though, Apple has leveraged its strong brand name and robust cash flow generation to invest in and grow its services business.The company's services segment offers customers a range of products, including Apple Music, Apple TV+, Apple Pay, iCloud, and more. The great thing about this business is that it offers much juicier margins than the sale of hardware products such as the iPhone, tablets, and laptops. In other words, as Apple's services revenue grows -- and as it captures a larger share of the company's total revenue -- that will work wonders for the company's bottom line.iPhone sales will likely remain strong for many more years, especially as Apple makes headway into various international markets. But the company's future is increasingly tied to its services segment, and that's something that should excite investors. Even with a $2.8 trillion market cap, Apple still has considerable room to grow. No wonder it is one of the largest holdings in Buffett's portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":422,"commentSize":123,"repostSize":0,"favoriteSize":4,"likeStatus":false,"favoriteStatus":false}}